Abstracts

Poster Session B

Tumor Immunology 2012 Poster Session B
Tuesday, December 4
12:30 p.m.-3:00 p.m.

In alphabetical order, not board assignment order

A natural plant-derived compound, Withaferin A, exploits the stress pathway to induce anti-tumor immunity. Annalise Smith, University of Miami, Miami, FL
A novel quantitative proteomics approach to identify proteins that elicit antibody responses in vaccinated pancreatic cancer patients. Darshil Jhaveri, Johns Hopkins University School of Medicine, Baltimore, MD
A potential of glypican-3-derived peptide vaccine therapy against cancer. Tetsuya Nakatsura, National Cancer Center Hospital East, Kashiwa, Japan
A targeted gene-delivery system for near infrared hyperthermia-induced expression of an immunotherapeutic gene. Helen Andersson, The Methodist Hospital Research Institute, Houston, TX
Abnormalities in cellular and humoral immunity in breast cancer patients resistant to endocrine therapy. Eva Zavadova, Charles University, Dept. Oncology, Prague, Czech Republic
An autopsy case of a hepatocellular carcinoma patient with remarkable tumor necrosis immediately following glypican-3-derived peptide vaccination. Yu Sawada, National Cancer Center Hospital East, Kashiwa, Japan
Analysis of immune responses and tumor protection in C57/Bl6 mice immunized with altered CD8 survivin peptide ligands. Yago Pico de Coaña, Karolinska Institutet, Stockholm, Sweden
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO-based immunotherapy. Mikayel Mkrtichyan, Cancer Center, Georgia Health Sciences University, Augusta, GA
Anti-tumor responses driven by alloreactivity. Loren Fast, Rhode Island Hospital, Providence, Rhode Island
Aptamer-targeted delivery of Smad3 or RNF111 siRNAs renders CD8+ T cells resistant to TGFß inhibition and potentiates vaccine-induced antitumor immunity. Randall Brenneman, Miller School of Medicine-University of Miami, Miami, FL
Aptamer-targeted siRNA-mediated inhibition of mTORC1 in antigen-primed CD8+ cytotoxic T lymphocytes enhances immunological memory and antitumor immunity. Alexey Berezhnoy, University of Miami Miller School of Medicine, Miami, FL
Ascitic IL-10 concentration is correlated to peritoneal tumor burden and a prognostic factor of peritoneal recurrence in colon cancer. Seung Chul Heo, Seoul National University College of Medicine, Seoul, Korea (Rep.)
Autologous T cell responses against patient-derived colorectal cancer xenografts. Jeffrey Chou, Fred Hutchinson Cancer Research Center, Seattle, WA
Beta2-microglobulin mutations as a favorable prognostic marker in microsatellite-unstable colorectal cancer. Anna Tikidzhieva, University Hospital Heidelberg, Heidelberg, Germany
CCL20-dependent cooperation between tumor-associated neutrophils and regulatory T cells promotes growth of castration-resistant prostate cancer. Purnima Dubey, Wake Forest School of Medicine, Winston Salem, NC
CD39+ cancer cells mediate immunosuppression reverted by CD39-blocking antibodies. Jeremy Bastid, OREGA-Biotech, Ecully, France
CD40 combined toll-like receptor-3 ligation restore morphine-induced reducing dendritic cells mediating immunity and anti-tumor effect. Ming-Cheng Chang, National Taiwan University Hospital, Taipei, Taiwan
CD8+FoxP3+ T cells: A new player in the immune response to ovarian cancer. Sara Kost, Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, BC, Canada
CD8αα+ langerin+ dendritic cells maintain the effector CD8 T cell population after adoptive transfer. John Gibbins, Malaghan Institute of Medical Research, Wellington, New Zealand
Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent cell death in natural killer cells. Kristoffer Hellstrand, University of Gothenburg, Gothenburg, Sweden
Clinical significance of FOXP3+ T cell heterogeneity in ovarian cancer. Ronald deLeeuw, Deeley Research Centre BCCA, Victoria, BC, Canada
Combining selective toll-like receptor 9 (TLR9) agonists and GM-CSF activity for potentiating cellular activation in active cell immunotherapy (ACI). Jason Chinn, Dendreon, Seattle, WA
Competition driven cancer immunoediting. Irina Kareva, Tufts University School of Medicine, Boston, MA
Control of in vivo spatio-temporal dynamics of antigen and adjuvant by a delivery system CHP nanogel markedly improves the immunogenicity and anti-tumor efficacy of long peptide cancer vaccine. Daisuke Muraoka, Mie University Graduate School of Medicine, Tsu, Japan
Cross-priming of CD8+ T cells is controlled by dipeptidyl peptidase 3 and thimet oligopeptidase 1 present in necrotic cells. Tim Greten, National Institutes of Health, Bethesda, MD
CXCL13-producing follicular helper CD4+ T cells infiltrating human breast cancer signal an organized immune response and predict a favorable clinical outcome. Karen Willard-Gallo, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities through enhancing antigen-specific T cell immune responses. Yu-Li Chen, Cathay General Hospital, Taipei, Taiwan
DNA damage response in responder lymphocytes reduces vaccine efficacy following alkylating chemotherapy. Adam Litterman, University of Minnesota, Minneapolis, MN
Eribulin mesylate alters immune homeostasis in mice bearing syngeneic tumors. Diana Albu, Eisai Inc., Andover, MA
Exposure-response relationship of intratumoral regulated IL-12 gene delivery under the control of an oral activator ligand in murine B16 model and melanoma patients. Lei Sun, ZIOPHARM Oncology Inc., Boston, MA
Flow cytometric analysis demonstrates prognostic significance of tumor infiltrating CD4+ T lymphocytes in patients with Diffuse Large B Cell Lymphoma receiving R-CHOP chemo-immunotherapy. Colm Keane, Princess Alexandra Hospital, Brisbane, Qld, Australia
FOXP1 truncated isoforms differentially regulate target genes in Diffuse Large B cell Lymphoma. Emily Camilleri, Griffith University, Gold Coast, Queensland, Australia
Galectin-1 expression related to hypoxia in primary human melanoma as a driver for metastatic progression: A target to promote anticancer immunotherapy. Stephen Ralph, Griffith University, Gold Coast, Queensland, Australia
Generation of MAGE-A4 ^230-239 peptide-specific cytotoxic T lymphocytes using an alloreactive approach. Tanja Lövgren, Cancer Center Karolinska (CCK), Dept. Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
Granulocyte macrophage colony stimulating factor (GM-CSF) pancreas tumor vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic cancer. Kevin Soares, Johns Hopkins Medical School, Baltimore, MD
Gut commensal bacteria promote anti-tumor innate immune responses in distant tumors after immunotherapy and chemotherapy. Noriho Iida, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health, Frederick, MD
Identification of novel immune check points and their implementation as mAb targets for cancer immunotherapy. Ofer Levy, Compugen LTD, Tel Aviv, Israel
IgE-independent hypersensitivity reactions are associated with prolonged survival in advanced pancreatic cancer patients receiving a GM-CSF cell-based vaccine plus cyclophosphamide (Cy) and cetuximab. Julie Ng, Johns Hopkins University School of Medicine, Baltimore, MD
IgG4 subclass antibodies impair anti-tumor immunity in melanoma. Panagiotis Karagiannis, King's College London, London, England
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Nobuyoshi Hiraoka, National Cancer Center Research Institute, Tokyo, Japan
Immune signatures of glioblastoma subtypes: Extrapolation from the Cancer Genome Atlas. Tiffany Doucette, The University of Texas MD Anderson Cancer Center, Houston, TX
Immunomodulation by tasquinimod: Combination with immunotherapy results in enhanced CD8 T cell responses and improved anti-tumor effects. Anders Olsson, Active Biotech AB, Lund, Sweden
Immunomodulation by tasquinimod: Skewing of tumor infiltrating myeloid cell populations. David Liberg, Active Biotech AB, Lund, Sweden
Immunomodulatory effects of LL-37/CRAMP in prostate cancer progression. Ha-Ram Cha, University of Alabama at Birmingham, Birmingham, AL
Immunotherapy as treatment for dogs with glioma. Michelle Goulart, University of Minnesota, Saint Paul, MN
Immunotherapy of solid tumors with IgE antibodies: Paradigm of a novel concept towards clinical application. Sophia Karagiannis, King's College London, London, United Kingdom, England
Improving the identification of beneficial mimotopes using a representative tumor-specific T cell receptor. Jill Slansky, University of Colorado School of Medicine, Denver, CO
In-vivo anti-cancer efficacy of recombinant mouse IL-17E in syngeneic mouse colon and melanoma models in balb/c mice. Robert Peralta, Lorus Therapeutics Inc., Toronto, Ontario, Canada
Low avidity tumor-specific CD8+ T cells are regulated by increased expression of pro-apoptotic proteins in tolerant mice. Chelsea Black, Johns Hopkins University School of Medicine, Baltimore, MD
Low-dose chemotherapy in combination with intratumoral regulated IL-12 gene delivery under the control of an oral activator induced a substantial anti-tumor effect in the murine 4T1 breast tumor model. John Barrett, ZIOPHARM Oncology Inc., Boston, MA
Low-dose cyclophosphamide therapy affects TNFR2+ CD4 T cells leading to changed effector to regulatory T cell ratios, with a potential impact on clinical responses in gynecological cancer patients. Mutsa Madondo, Vaccine and Infectious Diseases Laboratory, Department of Immunology, Monash University, Melbourne, Victoria, Australia
Minimum effective concentration of Paclitaxel improves the effectivity of dendritic cells transfected with tumor RNA. Marcela Camargo, Universidade Estadual Paulista – UNESP, Botucatu, SP, Brazil
miR-124 systemically enhances anti-tumor clearance by inhibiting STAT3 signaling and reversing glioma-associated immune suppression. Jun Wei, University of Texas MD Anderson Cancer Center, Houston, TX
Modulation of the M2 macrophage with miR-142-3p to induce therapeutic efficacy against glioblastoma. Shuo Xu, University of Texas MD Anderson Cancer Center, Houston, TX
MUC16 protects ovarian cancer cells from the cytolytic responses of human and murine natural killer cells and macrophages. Mildred Felder, University of Wisconsin-Madison, Madison, WI
Myeloid-derived suppressor cells from melanoma patients suppress T cell proliferation and are associated with a shorter disease-free interval. Martin McCarter, University of Colorado, Aurora, CO
Nanoparticle-based in vivo vaccines for cancer therapy. Kellie McConnell, The Methodist Hospital Research Institute, Houston, TX
Neural cells labeling with intracerebral ferumoxytol iron oxide nanoparticles in a rat model. Yingjen Wu, Oregon Health and Science University, Portland, OR
Novel dual-mode fluorine MRI, NIR fluorescent probe for non-invasive detection of tumor-associated inflammation. Brooke Helfer, Celsense Inc., Pittsburgh, PA
Novel MHC class I antibody fusions for cancer treatment. Martina Schmittnaegel, Roche Diagnostics GmbH, Penzberg, Germany
Porous silicon microparticles exhibit immunomodulatory effects leading to suppression of tumor growth. Ismail Meraz, Nanomedicine Department, The Methodist Hospital Research Institute, Houston, TX
Potential synergistic anti-tumor activity between sorafenib and lenalidomide in an orthotopic murine liver cancer model. Chiun Hsu, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
Preclinical testing of three immune adjuvants in vaccination therapy for invasive canine meningioma. Brian Andersen, University of Minnesota, Minneapolis, MN
Proof of glypican-3 (GPC3) peptide specific CTLs infiltrating into tumor tissue derived from advanced HCC patient vaccinated with GPC3 peptide. Toshiaki Yoshikawa, National Cancer Center Hospital East, Chiba, Japan
Protective immunizations using cultured peripheral blood cells. Kenneth Brasel, Dendreon, Seattle, WA
Radiotherapy promotes tumor-specific effector CD8+ T cells via DC activation. Anurag Gupta, Department of Oncology, University Hospital Zurich, Zurich, Switzerland
Regulation of tumor-specific CD8 T cells via interactions between galectin-3 and surface glycoproteins. Theodore Kouo, Johns Hopkins Medical Institutions, Baltimore, MD
Resensitization to CDDP or trail-mediated apoptosis in ovarian cancer cells by obatoclax. Melisa Martinez-Paniagua, Unidad de Investigación Médica en Inmunología e Infectología CMN “La Raza”, IMSS, Mexico, DF, Mexico
Restoring T cell immunosurveillance in pancreatic carcinoma using CD40 agonists. Gregory Beatty, University of Pennsylvania, Philadelphia, PA
Sunitinib enhanced the anti-cholangiocarcinoma action of cytokine-induced killer cells through the action on CD3+CD56+ cells. Adisak Wongkajornsilp, Mahidol University, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
Synergistic effects of αCTLA-4 and radiotherapy in the treatment of prostate cancer. Lisa Johnson, BC Cancer Agency, Victoria, BC, Canada
T cell costimulation in cancer immunotherapy with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. Ivan Martinez-Forero, CIMA-Universidad de Navarra, Pamplona, Spain
Targeting tumor-infiltrating macrophages decreases pancreatic tumor-initiating cells and improves chemotherapeutic responses by relieving immune suppression. David DeNardo, Washington University St. Louis School of Medicine, St. Louis, MO
Tasquinimod targets immunosuppressive myeloid cell populations and enhances immunotherapy in murine prostate cancer models. Li Shen, Roswell Park Cancer Institute, Buffalo, NY
The Heat Shock Protein receptor CD91 is necessary for tumor antigen cross-priming in vivo. Yu Zhou, University of Pittsburgh School of Medicine, Pittsburgh, PA
The influence of macrophage stimulation on lung cancer migration/invasion, proliferation, and treatment sensitivity. Timothy Rohrbach, University of Alabama at Birmingham, Birmingham, Alabama
The relation between Treg and cancer stem cells in microenvironment of head and neck squamous cell carcinoma. Jan Boucek, Department of Otorhinolaryngology, Head and Neck Surgery. Charles University in Prague, Prague, Czech Republic
The role of JNK isoforms in adenovirus-induced autophagy: Implications for cancer immunotherapy using oncolytic adenoviruses. Sarah Klein, University of Texas MD Anderson Cancer Center, Houston, TX
The Role of Th17 Cells in the Head and Neck Squamous Cell Carcinoma Evolution. Michal Zabrodsky, Department of Otorhinolaryngology, Head and Neck Surgery. Charles University, Prague, Czech Republic
Treatment of established dermal murine B16F10 melanoma with an attenuated Toxoplasma gondii eliminates the treated tumor and stimulates systemic anti-tumor immunity. Steven Fiering, Geisel Medical School at Dartmouth, Hanover, NH
Treatment of mouse glioma with delta24-RGD oncolytic adenovirus results in significant survival benefit that is accompanied by an anti-tumor immune response. Anne Kleijn, ErasmusMC, Rotterdam, The Netherlands
Tumor rejection driven by efficient Treg depletion is associated with a strong change in the tumor microenvironment. Oscar Salgado, Division of Molecular Immunology, German Cancer Research Center, Heidelberg, Germany
Tumor-educated CD11c+/CD11bint/Gr-1- regulatory dendritic cells show a mutated pattern of trafficking molecules implicated in cytokine secretion. Giulia Chiaruttini, ICGEB International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
Tumor-specific structural rearrangements as potential targets for anti-cancer vaccines. Spencer Martin, Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, BC, Canada
Tumor-specific T cells mediates bone loss and promotes bone metastatic colonization. Ana Carolina Monteiro, Instituto Oswaldo Cruz, Rio De Janeiro, Brazil
Up-regulation of DUSP1 by a novel HDAC inhibitor overcomes gefitinib resistance in non-small cell lung cancers. Ching-Chow Chen, College of Medicine, National Taiwan University, Taipei, Taiwan
Vaccination against microsatellite-unstable colorectal cancer with frameshift peptide antigens. Matthias Kloor, University Hospital Heidelberg, Heidelberg, Germany